An
estimated 813,000 people with diagnosed hepatitis C in the US have undergone
liver disease staging and meet the ‘highest’ or ‘high’ priority criteria for
immediate treatment, according to an analysis presented at the American Association for the Study of Liver
Diseases (AASLD) Liver Meeting last month in Boston. The number would be even

Nearly one-third of chronic hepatitis C patients
with liver cirrhosis and 12% with advanced fibrosis progressed to
decompensation within five years, and 23% and 11%, respectively, died,
according to a study presented at the
American Association for the Study of Liver
Diseases (AASLD) Liver Meeting last month in Boston. These findings underscore the
urgent need for

No new HIV infections have
occurred among more than 500 users of the Kaiser Permanente healthcare provider
system in the US in members using pre-exposure prophylaxis — better known as
PrEP.
However, condom use appears to be
declining among a subset of gay men, according to a small survey presented at a
December 1 forum commemorating

Difficult-to-treat hepatitis C patients with
liver cirrhosis who were not cured with a prior course of first-generation HCV
protease inhibitors had a sustained response rate of 96-97% when re-treated
with sofosbuvir/ledipasvir with ribavirin for 12 weeks or without ribavirin for
24 weeks, researchers reported at the
American Association for the Study of Liver
Diseases (AASLD) Liver

An interferon-free
regimen of sofosbuvir plus ledipasvir (Harvoni)
taken with ribavirin for 12 or 24 weeks led to sustained virological response
in nearly all HCV genotype 1patients
with fibrosis or less-advanced liver cirrhosis, researchers reported at the American
Association for the Study of Liver Diseases (AASLD) Liver Meeting last month in
Boston, United States. Response rates

Regimens containing sofosbuvir
(Sovaldi) – including sofosbuvir plus
simeprevir (Olysio) – work well for people
with hepatitis C genotype 1 in real-world use, which to date has included some
of the patients most urgently in need of treatment at the dawn of the
interferon-free era, according to a pair of presentations at the American
Association for

Most people with chronic hepatitis B who are
treated with tenofovir for eight years continued to maintain viral suppression,
researchers reported at the American
Association for the Study of Liver Diseases (AASLD) Liver Meeting earlier this month in
Boston, United States. Serological response rates continued to increase
over time and kidney and bone-related side-effects remained

 
A 12-week oral combination
of sofosbuvir plus the experimental NS5A inhibitor GS-5816 demonstrated high
sustained virological response rates for people with difficult-to-treat HCV
genotype 3 and other genotypes, according to phase 2 study findings presented at
the American Association for the Study of Liver
Diseases (AASLD) Liver Meeting last week in Boston. Reducing treatment duration

An all-oral regimen of
grazoprevir (MK-5172) and elbasvir (MK-8742), taken with or without
ribavirin for 12 weeks, demonstrated high sustained virological response (SVR) rates
for treatment-naive and treatment-experienced people with genotype 1 hepatitis
C virus (HCV), including people with liver cirrhosis and HIV and HCV co-infection,
researchers reported on Tuesday at
the American Association for the

Sofosbuvir/ledipasvir without
ribavirin and AbbVie’s 3D regimen (paritaprevir/ombitasvir plus dasabuvir) both
produced high sustained virological response rates for people with hepatitis C
virus (HCV) genotype 4, according to a pair of studies presented at the American Association for the Study of Liver
Diseases (AASLD) Liver Meeting this week in Boston, USA.
HCV genotype 4, the
most